<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33531379</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2332-7812</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title>
          <ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e963</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000963</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Investigate the value of including cerebellar degeneration-related protein 2-like (CDR2L) as a marker in commercial diagnostic tests for anti-Yo-associated paraneoplastic cerebellar degeneration (PCD).</AbstractText>
          <AbstractText Label="METHODS">We included sera and CSF samples from 24 patients with suspected PCD (6 of whom had PCD with underlying gynecologic or breast cancer), who were positive for Yo antibodies using the commercially available, paraneoplastic neurologic syndromes (PNS) 14 Line Assay from Ravo Diagnostika. The samples were further evaluated using the EUROLINE PNS 12 Ag Line Assay and a cell-based assay (CBA) from Euroimmun. For confirmation of positive lineblot results, we used indirect immunofluorescence of rat cerebellar sections. We also tested all samples in 2 assays developed in-house: a CBA for CDR2L and a Western blot analysis using recombinant cerebellar degeneration-related protein 2 (CDR2) and CDR2L proteins.</AbstractText>
          <AbstractText Label="RESULTS">In PNS 14 and PNS 12 Ag Line Assays, anti-CDR2 reactivity was observed for 24 (100%) and 20 (83%) of the 24 samples, respectively. Thirteen of 24 subjects (54%) were also positive using the Euroimmun CBA. Rat cerebellar immunofluorescence was the best confirmatory test. In our in-house CBA for CDR2L and Western blot for CDR2 and CDR2L, only the 6 patients with confirmed PCD reacted with CDR2L.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Commercially available tests for Yo antibody detection have low specificity for PCD because these assays use CDR2 as antigen. By adding a test for CDR2L, which is the major Yo antigen, the accuracy of PCD diagnosis greatly improved.</AbstractText>
          <AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class III evidence that a CBA for CDR2L accurately identifies patients with PCD.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Herdlevær</LastName>
            <ForeName>Ida</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4146-7606</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway. idaherd@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haugen</LastName>
            <ForeName>Mette</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazengia</LastName>
            <ForeName>Kibret</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Totland</LastName>
            <ForeName>Cecilie</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vedeler</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-0993-8906</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA>
        <NlmUniqueID>101636388</NlmUniqueID>
        <ISSNLinking>2332-7812</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000599484">CDR2L antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="N">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33531379</ArticleId>
        <ArticleId IdType="pmc">PMC8057066</ArticleId>
        <ArticleId IdType="doi">10.1212/NXI.0000000000000963</ArticleId>
        <ArticleId IdType="pii">8/2/e963</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Déchelotte B,
Muñiz-Castrillo S,
Joubert B, et al. . Diagnostic yield of commercial
immunodots to diagnose paraneoplastic neurologic syndromes.
Neurol Neuroimmunol Neuroinflamm
2020;7:e701. doi:
10.1212/NXI.0000000000000701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000701</ArticleId>
            <ArticleId IdType="pmc">PMC7136063</ArticleId>
            <ArticleId IdType="pubmed">32170044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F,
Delattre JY,
Antoine JC, et al. . Recommended diagnostic criteria for
paraneoplastic neurological syndromes. J Neurol
Neurosurg Psychiatry
2004;75:1135–1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii L,
Bost C,
Liblau R.
Immunological bases of paraneoplastic cerebellar degeneration
and therapeutic implications. Front Immunol
2020;11:991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7326021</ArticleId>
            <ArticleId IdType="pubmed">32655545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J,
Rosenfeld MR.
Paraneoplastic syndromes of the CNS.
Lancet Neurol
2008;7:327–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storstein A,
Monstad SE,
Haugen M, et al. . Onconeural antibodies: improved
detection and clinical correlations. J
Neuroimmunol
2011;232:166–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21093932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Brien TJ,
Pasaliaris B,
D'Apice A,
Byrne E.
Anti-Yo positive paraneoplastic cerebellar degeneration: a
report of three cases and review of the literature.
J Clin Neurosci
1995;2:316–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18638835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman A,
Opal P.
Paraneoplastic cerebellar degeneration with anti-Yo
antibodies—a review. Ann Clin Transl
Neurol
2016;3:655–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4999597</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raspotnig M,
Haugen M,
Thorsteinsdottir M, et al. . Cerebellar degeneration-related
proteins 2 and 2-like are present in ovarian cancer in patients with and
without Yo antibodies. Cancer Immunol
Immunother
2017;66:1463–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28710511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Totland C,
Aarskog NK,
Eichler TW, et al. . CDR2 antigen and Yo
antibodies. Cancer Immunol Immunother
2011;60:283–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024499</ArticleId>
            <ArticleId IdType="pubmed">21080165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herdlevær I,
Kråkenes T,
Schubert M,
Vedeler CA.
Localization of CDR2L and CDR2 in paraneoplastic cerebellar
degeneration. Ann Clin Translational Neurol
2020;7:2231–2242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7664253</ArticleId>
            <ArticleId IdType="pubmed">33009713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storstein A,
Krossnes BK,
Vedeler CA.
Morphological and immunohistochemical characterization of
paraneoplastic cerebellar degeneration associated with Yo
antibodies. Acta Neurol Scand
2009;120:64–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krakenes T,
Herdlevaer I,
Raspotnig M,
Haugen M,
Schubert M,
Vedeler CA.
CDR2L is the major Yo antibody target in paraneoplastic
cerebellar degeneration. Ann Neurol
2019;86:316–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31148214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-García R,
Martínez-Hernández E,
Saiz A,
Dalmau J,
Graus F.
The diagnostic value of onconeural antibodies depends on how
they are tested. Front Immunol
2020;11:1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7372120</ArticleId>
            <ArticleId IdType="pubmed">32760403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert M,
Panja D,
Haugen M,
Bramham CR,
Vedeler CA.
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell
calcium homeostasis. Acta Neuropathol
2014;128:835–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4231287</ArticleId>
            <ArticleId IdType="pubmed">25341622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Donovan B,
Mandel-Brehm C,
Vazquez SE, et al. . High resolution epitope mapping of
anti-Hu and anti-Yo autoimmunity by programmable phage
display. Brain Commun
2020;2:fcaa059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7425417</ArticleId>
            <ArticleId IdType="pubmed">32954318</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33531379</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2332-7812</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title>
          <ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e963</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000963</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Investigate the value of including cerebellar degeneration-related protein 2-like (CDR2L) as a marker in commercial diagnostic tests for anti-Yo-associated paraneoplastic cerebellar degeneration (PCD).</AbstractText>
          <AbstractText Label="METHODS">We included sera and CSF samples from 24 patients with suspected PCD (6 of whom had PCD with underlying gynecologic or breast cancer), who were positive for Yo antibodies using the commercially available, paraneoplastic neurologic syndromes (PNS) 14 Line Assay from Ravo Diagnostika. The samples were further evaluated using the EUROLINE PNS 12 Ag Line Assay and a cell-based assay (CBA) from Euroimmun. For confirmation of positive lineblot results, we used indirect immunofluorescence of rat cerebellar sections. We also tested all samples in 2 assays developed in-house: a CBA for CDR2L and a Western blot analysis using recombinant cerebellar degeneration-related protein 2 (CDR2) and CDR2L proteins.</AbstractText>
          <AbstractText Label="RESULTS">In PNS 14 and PNS 12 Ag Line Assays, anti-CDR2 reactivity was observed for 24 (100%) and 20 (83%) of the 24 samples, respectively. Thirteen of 24 subjects (54%) were also positive using the Euroimmun CBA. Rat cerebellar immunofluorescence was the best confirmatory test. In our in-house CBA for CDR2L and Western blot for CDR2 and CDR2L, only the 6 patients with confirmed PCD reacted with CDR2L.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Commercially available tests for Yo antibody detection have low specificity for PCD because these assays use CDR2 as antigen. By adding a test for CDR2L, which is the major Yo antigen, the accuracy of PCD diagnosis greatly improved.</AbstractText>
          <AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class III evidence that a CBA for CDR2L accurately identifies patients with PCD.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Herdlevær</LastName>
            <ForeName>Ida</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4146-7606</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway. idaherd@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haugen</LastName>
            <ForeName>Mette</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazengia</LastName>
            <ForeName>Kibret</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Totland</LastName>
            <ForeName>Cecilie</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vedeler</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-0993-8906</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA>
        <NlmUniqueID>101636388</NlmUniqueID>
        <ISSNLinking>2332-7812</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000599484">CDR2L antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="N">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33531379</ArticleId>
        <ArticleId IdType="pmc">PMC8057066</ArticleId>
        <ArticleId IdType="doi">10.1212/NXI.0000000000000963</ArticleId>
        <ArticleId IdType="pii">8/2/e963</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Déchelotte B,
Muñiz-Castrillo S,
Joubert B, et al. . Diagnostic yield of commercial
immunodots to diagnose paraneoplastic neurologic syndromes.
Neurol Neuroimmunol Neuroinflamm
2020;7:e701. doi:
10.1212/NXI.0000000000000701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000701</ArticleId>
            <ArticleId IdType="pmc">PMC7136063</ArticleId>
            <ArticleId IdType="pubmed">32170044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F,
Delattre JY,
Antoine JC, et al. . Recommended diagnostic criteria for
paraneoplastic neurological syndromes. J Neurol
Neurosurg Psychiatry
2004;75:1135–1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii L,
Bost C,
Liblau R.
Immunological bases of paraneoplastic cerebellar degeneration
and therapeutic implications. Front Immunol
2020;11:991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7326021</ArticleId>
            <ArticleId IdType="pubmed">32655545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J,
Rosenfeld MR.
Paraneoplastic syndromes of the CNS.
Lancet Neurol
2008;7:327–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storstein A,
Monstad SE,
Haugen M, et al. . Onconeural antibodies: improved
detection and clinical correlations. J
Neuroimmunol
2011;232:166–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21093932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Brien TJ,
Pasaliaris B,
D'Apice A,
Byrne E.
Anti-Yo positive paraneoplastic cerebellar degeneration: a
report of three cases and review of the literature.
J Clin Neurosci
1995;2:316–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18638835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman A,
Opal P.
Paraneoplastic cerebellar degeneration with anti-Yo
antibodies—a review. Ann Clin Transl
Neurol
2016;3:655–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4999597</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raspotnig M,
Haugen M,
Thorsteinsdottir M, et al. . Cerebellar degeneration-related
proteins 2 and 2-like are present in ovarian cancer in patients with and
without Yo antibodies. Cancer Immunol
Immunother
2017;66:1463–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28710511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Totland C,
Aarskog NK,
Eichler TW, et al. . CDR2 antigen and Yo
antibodies. Cancer Immunol Immunother
2011;60:283–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024499</ArticleId>
            <ArticleId IdType="pubmed">21080165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herdlevær I,
Kråkenes T,
Schubert M,
Vedeler CA.
Localization of CDR2L and CDR2 in paraneoplastic cerebellar
degeneration. Ann Clin Translational Neurol
2020;7:2231–2242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7664253</ArticleId>
            <ArticleId IdType="pubmed">33009713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storstein A,
Krossnes BK,
Vedeler CA.
Morphological and immunohistochemical characterization of
paraneoplastic cerebellar degeneration associated with Yo
antibodies. Acta Neurol Scand
2009;120:64–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krakenes T,
Herdlevaer I,
Raspotnig M,
Haugen M,
Schubert M,
Vedeler CA.
CDR2L is the major Yo antibody target in paraneoplastic
cerebellar degeneration. Ann Neurol
2019;86:316–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31148214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-García R,
Martínez-Hernández E,
Saiz A,
Dalmau J,
Graus F.
The diagnostic value of onconeural antibodies depends on how
they are tested. Front Immunol
2020;11:1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7372120</ArticleId>
            <ArticleId IdType="pubmed">32760403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert M,
Panja D,
Haugen M,
Bramham CR,
Vedeler CA.
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell
calcium homeostasis. Acta Neuropathol
2014;128:835–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4231287</ArticleId>
            <ArticleId IdType="pubmed">25341622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Donovan B,
Mandel-Brehm C,
Vazquez SE, et al. . High resolution epitope mapping of
anti-Hu and anti-Yo autoimmunity by programmable phage
display. Brain Commun
2020;2:fcaa059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7425417</ArticleId>
            <ArticleId IdType="pubmed">32954318</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
